跳至主要内容
临床试验/NCT01787448
NCT01787448已完成1 期

Repeat-insult Patch Test (Ript) of Ibuprofen 5% Topical Gel in Human Volunteers

Pfizer1 个研究点 分布在 1 个国家目标入组 234 人开始时间: 2013年1月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
1 期
状态
已完成
发起方
Pfizer
入组人数
234
试验地点
1
主要终点
Dermal sensitization potential

研究概览

简要总结

This study is being conducted to determine the potential of Ibuprofen 5% Topical Gel and its vehicle gel to cause sensitization after repeated topical application to healthy skin of human subjects under controlled conditions.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Single Group
主要目的
Basic Science
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Healthy male or female subjects 18 years of age or older, female subjects of childbearing potential and males are using an acceptable form of birth control, subjects are free of any systemic or dermatologic disorder

排除标准

  • Have any visible skin disease at the application site, not willing to stop use of systemic or topical analgesics, corticosteroids, or antihistamines, not willing to stop use of sunscreens, creams, or similar products on the back during the study

研究组 & 干预措施

Ibuprofen 5% topical gel

Experimental

干预措施: Topical gel vehicle (Drug)

Topical gel vehicle

Experimental

干预措施: Topical gel vehicle (Drug)

Sodium lauryl sulfate 0.1%

Active Comparator

干预措施: Sodium lauryl sulfate 0.1% (Drug)

Sodium chloride solution 0.9% (saline)

Sham Comparator

干预措施: Sodium chloride solution 0.9% (saline) (Drug)

结局指标

主要结局

Dermal sensitization potential

时间窗: 24-72 hours after last patch removal

次要结局

  • Cumulative Irritancy(48-72 hours after each patch application)
  • Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)(During study through 28 days after last product application)

研究者

发起方
Pfizer
申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验